It is a “biosimilar” drug. — TNSMany American medical professionals look to biosimilar drugs as a way to increase competition and give consumers cheaper options – much as generic drugs do – and they point to the more robust use of these products in Europe to cut costs. Yet the US has been slower to adopt biosimilar drugs since the first such medicine was approved in 2015. Other drugmakers can’t exactly reproduce these biologic drugs by following chemical recipes as they do for generic versions of conventional drugs. Instead, biosimilar versions of biologic drugs are generally made from the same types of materials as the original biologics and must be “highly similar” to them to be approved by the US FDA.

Source: The Star October 09, 2021 00:00 UTC